On Tuesday, Jan. 10, Global Healthcare will become Reuters Health Rounds, a newsletter curated by Nancy Lapid, editor in charge of Reuters Health. Reuters Health Rounds will be sent on Tuesdays and Thursdays.
Roche Holding AG said on Wednesday the U.S. Food and Drug Administration (FDA) had approved its monoclonal antibody for treating COVID-19 in hospitalized adult patients.
Ever since Gerald Muwonge tested positive for HIV eight years ago, keeping his viral load in check has meant carrying around vials of pills for his daily treatment regimen while dodging the stigma this could mean for a gay man in Uganda.
The United States has released doses of the antiviral flu drug Tamiflu through a national stockpile for the flu season amid surging demand, the health department said on Wednesday.
The spread of bird flu has accelerated in the past weeks in France, the European Union's second largest poultry producer, the farm ministry said on Wednesday, raising concern of further shortages.
Dozens of hearses queued outside a Beijing crematorium on Wednesday, even as China reported no new COVID-19 deaths in its growing outbreak, sparking criticism of its virus accounting as the capital braces for a surge of cases.
Germany's BioNTech said on Wednesday it has completed construction of its first vaccine factory made from shipping containers called 'BioNtrainer' being sent to Africa.
China may be struggling to keep a tally of COVID-19 infections as the country experiences a big spike in cases, a senior World Health Organization official said on Wednesday, amid concerns about a lack of data from the country.
BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study, the German vaccine maker said on Wednesday.
Berlin has sent its first batch of BioNTech COVID-19 vaccines to China to be administered initially to German expatriates, a German government spokesperson said on Wednesday, the first foreign coronavirus vaccine to be delivered to the country.
Zynerba Pharmaceuticals Inc on Wednesday delayed the timeline for reporting key data from a trial of its cannabis-based drug to treat a rare genetic disorder, citing difficulties in enrolling patients amid a rise in respiratory illnesses.
